Alpha Healthcare Acquisition III in an 8-K said shareholders voted in favor of merging with Carmell Therapeutics, a Phase 2 stage regenerative medicine platform company developing allogeneic plasma-based biomaterials for active soft tissue repair, aesthetics and orthopedic indications.
The regulatory filing did not disclose stock redemptions, if any. At deal announcement in January, the combined company was expecting to receive gross proceeds of $154 million at closing.
Last week Alpha III said it signed a forward purchase agreement with Meteora Capital Partners and its affiliated funds. Under the agreement, Meteora will purchase up to 9.5% of the total number of Alpha’s outstanding shares.
The SPAC also inked a non-redemption agreement with Meteora covering 100,000 shares. Read more.
